The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

New, innovative therapies must be added to the existing arsenal of treatments for adult female acne, according to a ...

The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not ...

Black historical romance novelist Beverly Jenkins is known for centering Black love throughout history. This month, her work ...

A new study suggests popular weight-loss drugs like Ozempic and Zepbound may be linked to rare eye conditions that could ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, provided progress updates on its Phase 1b, 12-week ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive growth. The number of Americans taking GLP-1s for weight loss rose more ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

Growing demand for tryptamine APIs stems from their anti-cancer potential, pharmaceutical uses, and role as a neurotransmitter modulator i ...